地理萎缩
医学
临床试验
补语(音乐)
黄斑变性
试验药物
专家意见
重症监护医学
补体系统
妥珠单抗
药理学
免疫学
病理
精神科
疾病
生物
免疫系统
表型
互补
基因
英夫利昔单抗
生物化学
作者
Lorenzo Ferro Desideri,Dmitri Artemiev,Enrico Bernardi,Karin Paschon,Souska Zandi,Martin Zinkernagel,Rodrigo Anguita
标识
DOI:10.1080/13543784.2023.2276759
摘要
Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA.This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Specifically, it focuses on the recent FDA approved pegcetacoplan, a C3 complement inhibitor, and avacincaptad pegol, a C5 complement inhibitor, highlighting their potential efficacy and safety profiles based on clinical trial data.FDA approval of intravitreal pegcetacoplan and avacincaptad pegol marks significant progress in the landscape of GA treatment. However, variable results from trials underscore the complex nature of GA and the importance of patient selection. Complement inhibition holds promise, but ongoing research is vital to refine treatment strategies and offer improved outcomes for GA patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI